CENTRAL TRUST Co held its position in Hologic, Inc. (NASDAQ:HOLX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,683 shares of the medical equipment provider’s stock at the end of the second quarter. CENTRAL TRUST Co’s holdings in Hologic were worth $212,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Victory Capital Management Inc. increased its stake in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the last quarter. UBS Asset Management Americas Inc. increased its stake in shares of Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock valued at $58,032,000 after buying an additional 798,541 shares during the last quarter. Finally, Pictet Asset Management Ltd. increased its stake in shares of Hologic by 69.4% in the first quarter. Pictet Asset Management Ltd. now owns 1,585,461 shares of the medical equipment provider’s stock valued at $67,461,000 after buying an additional 649,632 shares during the last quarter. Institutional investors and hedge funds own 94.46% of the company’s stock.
Hologic, Inc. (HOLX) opened at 39.25 on Monday. The stock has a market capitalization of $11.01 billion, a PE ratio of 14.62 and a beta of 0.90. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The company’s 50 day moving average is $45.06 and its 200-day moving average is $42.98.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.51 earnings per share. Analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “CENTRAL TRUST Co Maintains Stake in Hologic, Inc. (HOLX)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/07/hologic-inc-holx-stake-maintained-by-central-trust-co-updated-updated.html.
HOLX has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Royal Bank Of Canada decreased their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday. Deutsche Bank AG cut their target price on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday. Stifel Nicolaus raised their target price on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $48.64.
In related news, Director Lawrence M. Levy sold 2,960 shares of the company’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $44.54, for a total value of $131,838.40. Following the completion of the sale, the director now owns 45,634 shares of the company’s stock, valued at $2,032,538.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the company’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $43.44, for a total transaction of $434,617.20. Following the completion of the sale, the insider now directly owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The disclosure for this sale can be found here. Insiders sold 63,562 shares of company stock valued at $2,802,013 in the last three months. 0.79% of the stock is currently owned by insiders.
About Hologic
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
